SCHEMBL2803784

SCHEMBL2803784

CO[C@@H]1O[C@@H](C)[C@H](OCc2ccccc2)[C@@H](O)[C@H]1O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 1/20 0.45
SSTR5 P35346 2/20 0.43
SSTR1 P30872 1/20 0.43
SSTR2 P30874 1/20 0.43
SSTR4 P31391 1/20 0.43
SSTR3 P32745 1/20 0.43
BCHE P06276 2/20 0.41
SLC6A2 P23975 1/20 0.40
LGALS3 P17931 2/20 0.40
PDPK1 O15530 1/20 0.40
MTOR P42345 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
GJB2 P29033 1/20 0.37
MGAM O43451 1/20 0.36
SI P14410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13129833 1.00 LGALS8 (0.45) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL8328774 0.91 SSTR5 (0.46) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL19620385 0.91 SSTR5 (0.46) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL19226930 0.91 SSTR5 (0.46) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL19620495 0.91 SSTR5 (0.46) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL9617274 0.91 PDPK1 (0.42) SSTR5SSTR1SSTR2SSTR4SSTR3
SCHEMBL9503678 0.89 SSTR5 (0.41) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL7892058 0.89 SSTR5 (0.41) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL8332110 0.89 SSTR5 (0.46) LGALS8SSTR5SSTR1SSTR2SSTR4
SCHEMBL22212491 0.87 LGALS8 (0.49) LGALS8SSTR5SSTR1SSTR2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119586700-A Pet food for improving excreta peculiar smell and preparation method thereof 江苏省农业科学院 2025-03-11 CN disclosed
US-10087242-B2 Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X INSTITUT PASTEUR (FR) 2018-10-02 US disclosed
EP-2164521-B1 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X PASTEUR INSTITUT (FR) 2018-09-12 EP disclosed
US-20150050282-A1 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X INSTITUT PASTEUR (FR) 2015-02-19 US disclosed
US-8815239-B2 Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X INSTITUT PASTEUR (FR) 2014-08-26 US disclosed
US-20100239584-A1 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X INSTITUT PASTEUR (FR) 2010-09-23 US disclosed
EP-2164521-A2 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST<I>SHIGELLA FLEXNERI</I>SEROTYPE 3A AND X Institut Pasteur (FR) 2010-03-24 EP disclosed
WO-2008155487-A2 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X INSTITUT PASTEUR (FR) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10087242-B2 Glycoconjugates and use thereof as vaccine against Shigella flexneri serotype 3a and X ST3GAL3, SI, STT3A LGALS8 130/4885SSTR5 684/4885SSTR1 1053/4885
US-20100239584-A1 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X ST3GAL3, SI, STT3A LGALS8 130/4885SSTR5 684/4885SSTR1 1053/4885
US-20150050282-A1 GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3a AND X ST3GAL3, SI, STT3A LGALS8 130/4885SSTR5 684/4885SSTR1 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.